



nci

NORTHERN CLINICS OF İSTANBUL

VOL 12 • NO 3 • YEAR 2025

P ISSN 2148-4902

E ISSN 2536-4553

Journal Abbreviation: North Clin Istanb

- Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population
- Determination of urinary iodine excretion and iodine deficiency in school-age children aged 7-11 after mandatory iodization in Canakkale, Türkiye
- *Candida auris* infection at a pediatric burn center: Treatment and infection control measures
- Evaluation of indoor air pollution in children with asthma
- The predictive power of albumin-based composite indicators for mortality in patients with aspiration pneumonia
- Predicting mortality in necrotizing fasciitis: Retrospective evaluation of 69 cases
- The role of C-reactive protein and albumin combined indexes in predicting the need for intubation in acute heart failure: A prospective observational study
- Sarcopenia in patients with multiple myeloma and autologous hematopoietic stem cell transplantation

INDEXED IN PUBMED,
EUROPE PMC, WEB
OF SCIENCE, DOAJ,
TRDİZİN, THE TURKIYE
SCIENCE CITATION
INDEX, TÜRKMEDLINE,
EBSCO, CEEAS, SCOPUS,
CLIO, PROQUEST, OUCI,
SCILIT AND HINARI/
RESEARCH4LIFE.



NORTHERN CLINICS OF ISTANBUL İSTANBUL KUZEY KLİNİKLERİ

EDITOR-IN-CHIEF

Berna Terzioğlu Bebitoğlu, MD.

EDITORS*

Mustafa Aldag, MD. Betül Sozeri, MD.
Sema Basat, MD. Kemal Tekesin, MD.
Neslihan Büyükmurat, MD. Aysel Tekesin, MD.
Tolga Canbak, MD. İlkin Zindancı, MD.
Mustafa Tümtürk, MD.

MANAGING EDITOR

Kemal Tekesin, MD.

STATISTICAL EDITOR

Nurdan Colakoglu

SCIENTIFIC COMMITTEE*

Didem Tuba Akcalı, MD.	Mehmet Doğanay, MD.	Umut Kefeli, MD.	Necdet Sağlam, MD.
İlknur Aktas, MD.	Dilek Erdoğan Ari, MD.	Zeid J. Khitan, MD.	Abdurrahman Şahin, MD.
Mustafa Aldag, MD.	Yuksel Ersoy, MD.	Tayfun Kirazlı, MD.	İlhan Sanverdi, MD.
Mustafa Aldemir, MD.	Duygu Geler Kulcu, MD.	Gurkan Kiran, MD.	Tarik Sapci, MD.
Orhan Alimoglu, MD.	Kaan Gideroglu, MD.	Cemal Kocaaslan, MD.	Ayşe Banu Sarıfakioğlu, MD.
Nuri Aydın, MD.	Ahmet Gocmen, MD.	O. Emek Kocaturk Goncu, MD.	Fatih Saygılı, MD.
Gurhan Bas, MD.	Mehmet Zafer Goren, MD.	Cevdet Ugur Kocogullari, MD.	Mehmet Selcuki, MD.
Ozlem Baysal, MD.	Aysegul Gunduz, MD.	Sukran Kose, MD.	Ali Sürmelioglu, MD.
Basak Bilir Kaya, MD.	Abdullah Emre Guner, MD.	Turkan Kudsioğlu, MD.	Seniha Senbayrak, MD.
Hasan Bombaci, MD.	Ozlem Guneyssel, MD.	Carlo A. Mallio, MD.	Ozlem Tanrioer, MD.
Derya Buyukkayhan, MD.	Melek Gura Celik, MD.	Kemal Memisoglu, MD.	Sait Terzi, MD.
Mustafa Caliskan, MD.	Melih Atahan Guven, MD.	Aysel Milanlioglu, MD.	Gulnur Tokuc, MD.
Kazim Capaci, MD.	Mert Ilker Hayiroglu, MD.	Murat Muhcu, MD.	Filiz Topaloglu Demir, MD.
Turhan Caskurlu, MD.	Mine Hekimgil, MD.	Sait Naderi, MD.	Ismail Turkmen, MD.
Erhan Celikoglu, MD.	Seyhan Hidiroglu, MD.	Kemal Nas, MD.	Feyza Unlu Ozkan, MD.
Ali Riza Cenk Celebi, MD.	Afitap Icagasioglu, MD.	Cagatay Nuhoglu, MD.	Sezgin Vatansever, MD.
Beyhan Cengiz Ozyurt, MD.	Ates Kadioglu, MD.	Tamer Okay, MD.	Ayhan Verit, MD.
Tongabay Cumurcu, MD.	Atila Karaalp, MD.	Muhammed Fatih Onsuz, MD.	Destina Yalcin, MD.
Seema Dayal, MD.	Ayşe Serap Karadag, MD.	Melike Ozcelik, MD.	Tuba Yavuzsen, MD.
Gizem Dinler Doganay, MD.	Ihsan Muhammet Karaman, MD.	Kamil Ozdil, MD.	Sema Yilmaz, MD.
Sibel Dogan, MD.	Semra Kayatas Eser, MD.	H. Isin Ozisik Karaman, MD.	Baris Yilmaz, MD.
			Ebru Zemheri, MD.

*The editorial board list is sorted alphabetically by surname.



NORTHERN CLINICS OF ISTANBUL
İSTANBUL KUZEY KLİNİKLERİ

YEAR 2025

VOLUME 12

NUMBER 3

P ISSN 2148 - 4902

E ISSN 2536 - 4553

OWNERSHIP AND ACCOUNTABILITY FOR CONTENTS

Kemal Memisoglu, MD.
(Minister of Health)

MANAGING EDITOR

Kemal Tekesin, MD.

EXECUTIVE OFFICE

Istanbul Provincial Health Directorate, Health Services Presidency,
Seyitnizam Mah., Mevlana Cad., No: 85, İl Sağlık Müdürlüğü Ek Hizmet Binası 11, Zeytinburnu, İstanbul-Türkiye
Phone: +90 216 632 18 18, +90 216 632 49 06
Fax: +90 212 516 25 49
<https://northcliniist.com>
e-mail: ahmet.keskin@ncliniist.com

Indexed in PubMed, Europe PMC, Web of Science, DOAJ, TRDIZIN, the Türkiye Science Citation Index, TurkMedline, EBSCO, CEEAS, Scopus, CLIO, ProQuest, OUCI, Scilit and Hinari/Research4Life.

PUBLISHER

KARE PUBLISHING
Göztepe Mahallesi,
Fahrettin Kerim Gökay Caddesi, No: 200,
Daire: 2, Kadıköy, İstanbul, Türkiye
Tel: +90 216 550 61 11
Fax: +90 216 550 61 12
<http://www.karepb.com>
e-mail: kare@karepb.com

PRESS

YILDIRIM PRINTING HOUSE
Yuzyıl Mah., Massit Matbaacılar Sitesi,
1. Cad., No: 101, Bağcılar, İstanbul, Türkiye
Tel: +90 212 629 80 37
Fax: +90 212 629 80 39

INFO

Press date: June 2025
Circulation: 50
Type of publication: Periodical

DESIGN

Neslihan Çakır
neslihan.cakir@karepb.com

Northern Clinics of Istanbul (NCI) is a peer-reviewed journal published 6 issues in a year.

This publication is printed on paper that meets the international standard ISO 9706:1994.

National Library of Medicine recommends the use of permanent, acid-free paper in the production of biomedical literature.



IV

Instructions for the authors

ORIGINAL ARTICLES

- 269–276** **Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population**
Emeksiz HC
- 277–284** **Determination of urinary iodine excretion and iodine deficiency in school-age children aged 7–11 after mandatory iodization in Canakkale, Turkiye**
Cevik K, Aylanc H
- 285–289** ***Candida auris* infection at a pediatric burn center: Treatment and infection control measures**
Ozen S, Gulhan B, Demir S, Turan Uzuntas S, Yahsi A, Kanik Yuksek S, Erat T, Guney AY, Guder L, Bayhan GI, Dinc B, Azili MN, Senel E, Ozkaya Parlakay A
- 290–297** **Evaluation of indoor air pollution in children with asthma**
Cekic S, Canitez Y, Karali Z, Bilgic E, Ortac H, Yuksel H, Sapan N
- 298–306** **The predictive power of albumin-based composite indicators for mortality in patients with aspiration pneumonia**
Akkok B, Bozkus F, Atilla N, Kahraman H
- 307–313** **Predicting mortality in necrotizing fasciitis: Retrospective evaluation of 69 cases**
Celik K, Danis F, Kudu E
- 204–210** **Comparative analysis of single-dose platelet-rich plasma and hyaluronic acid therapies in knee osteoarthritis: A 12-week follow-up study**
Karabas C, Akyildiz Tezcan E
- 314–320** **The role of C-reactive protein and albumin combined indexes in predicting the need for intubation in acute heart failure: A prospective observational study**
Algin A, Ozkan A, Yusufoglu K, Ozdemir S, Afacan MA
- 321–326** **Sarcopenia in patients with multiple myeloma and autologous hematopoietic stem cell transplantation**
Demirci U, Korkmaz U, Umit EG, Demir AM
- 327–336** **Examination of osteosarcopenia in patients over 65 years old with hip fracture**
Cakmak S, Turkmen I, Kulali F, Saglam N, Cakin Unnu S, Ucak Basat S
- 337–343** **Assessment of interobserver variability in Gleason grading for prostate carcinoma**
Cinar I, Cinar E
- 344–351** **Tenascin-C levels in polycystic ovary syndrome and polycystic ovarian morphology**
Koksal MK, Ozturk UK, Keles E, Arslan B, Engin Ustun Y
- 352–358** **Effects of the february 6 earthquake on the agents growing in urine cultures and antibiotic resistance rates**
Bugday MS, Oksuz E, Gunduz A, Inceoglu F
- 359–371** **Contextual reading and analysis of the team's narratives about the system in which clinical education and healthcare processes are experienced**
Saracoglu M, Yildiz Inanici S, Gulpinar MA

REVIEWS

- 372–377** **Usability assessments in clinical decision support systems**
Cubukcu HC, Canbaz H
- 378–384** **Risk of cancer and conventional syntethic DMARDS: A narrative review**
Skare T, de Carvalho JF

LETTER TO THE EDITOR

- 385** **Orbital Doppler ultrasonography evaluation in patients with ankylosing spondylitis:
A prospective study**
Resorlu M, Ertem SB

- 386** **AUTHORS' REPLY**

NORTHERN CLINICS OF ISTANBUL - NCI is a peer-reviewed, open-access, international journal published by the Istanbul Provincial Health Directorate, Health Services Presidency (IHD). The NCI is printed 6 times a year. Free full-text articles in English are available at www.kuzeyklinikleri.com. The NCI is indexed in PubMed, Europe PMC, Web of Science, DOAJ, TRDIZIN, the Türkiye Science Citation Index, TürkMedline, EBSCO, CEEAS, Scopus, CLIO, ProQuest, OUCI, Scilit and Hinari/Research4Life. The journal publishes research, interesting case reports, letters to the editor, review articles, editorial comments, medical news, and guidelines. The NCI accepts manuscripts written in English. Opinions presented in published articles do not represent official endorsement of the IHD.

Manuscripts should be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which is regularly updated by the International Committee of Medical Journal Editors (ICMJE), and available at <http://www.icmje.org>.

ARTICLE TYPES

The NCI publishes the kinds of articles briefly described below.

Research Articles: These are articles on original clinical (conducted with healthy subjects or patients) or experimental (human, animal or in-vitro trials) research performed in all fields.

Case Reports: This section contains reports on interesting, instructive or rarely seen cases.

Review Articles: Reviews are usually written at the invitation of the editors. The NCI publishes clinical review articles related to the natural course of diseases, updated diagnostic and therapeutic approaches of concern to clinicians and specialists in basic sciences that encompass genetic, physiological, and pharmacological aspects of the underlying mechanisms of diseases, and reviews about state-of-the-art treatment strategies, technological advancements, and newly approved drugs.

Editorial Comments: This section contains editors' comments, reviews, and other relevant items.

Letters to the Editor: These are comments, criticism and contributions in response to a paper published in the NCI. The author(s) of a criticized article has the right to reply. The article that is the subject of the comments should be listed in the references section. Letters must be sent to the editor within 4 weeks following publication of the subject article in the NCI.

PREPARATION OF MANUSCRIPT

General Format: All manuscripts should be typewritten on A4 white paper, and 2.5 cm-wide margins should be left on all sides. The references should be numbered consecutively in the order of their first mention in the text. All text material, including references, footnotes, and table and figure legends, should be typed using double-spacing in an 11 point font with left alignment and without hyphenated line breaks. The fonts Times New Roman or Arial should be used in the text, for symbols, and all other special characters. Please use the editing features of your word processing program to type bold or italic letters, mathematical symbols, Greek letters, subscript and superscript characters. Please take care not to confuse the letters O and I with the numerals 0 and 1. To set a left indent for a paragraph, click the TAB button once. Only the International System of Units (SI) should be used for units of measurement. Abbreviations and acronyms should be written in parentheses following the full name or an explanation of the usage should be provided just after the first appearance in the text. Please review the final version of the manuscript very carefully, especially for formatting and editing errors.

All pages of the manuscript should be consecutively numbered starting from the first page (page 1, Turkish abstract (Turkish authors only); page 2, English abstract, etc.). Page numbers should be indicated on the upper right-hand corner of each page. Final version of the manuscript should be in ".doc" or ".rtf" format. Manuscripts submitted in ".pdf" format will not be accepted.

Accepted manuscripts are copy-edited for grammar, punctuation, format, and clarity. Artificial intelligence technology is partially used in the English language correction of articles. A PDF proof of the manuscript is sent to the corresponding author and their publication approval is requested within 2 days of receipt of the proof.

Manuscript Sections: All research articles must contain the following sections: (1) Title page, (2) Abstract with keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Conflict of interest, (9) Funding resources, (10) References, (11) Legends of the figures, (12) Tables, (13) Figures. In case of need, presentation of Methods, Results, and Discussion sections under subheadings is preferred. Case reports should be presented following abstract section, under headings of introduction, case presentation, and discussion. In review articles, appropriate headings can be used in accordance with the development of the manuscript. Sections of the manuscript in order of their appearance in the text with relevant explanations are listed below.

Title Page: A separate title page should be submitted with all manuscripts and this page should include:

- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name, affiliation(s), ORCID ID, and highest academic degree(s) of the author(s),
- Details of any grant or other sources of support,
- Name, address, telephone (including mobile phone number) and fax numbers, and email address of the corresponding author,
- Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill authorship criteria.
- Authors should disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors should assert that there is no plagiarism in their paper, including in text and images produced by the AI -if any- and must ensure there is appropriate

ate attribution of all quoted material, including full citations. Authors who used AI technology to conduct the study should describe its use in the methods section in sufficient detail.

Abstract: The abstract should be written on a separate page. It should contain at most 250 words, and be structured as follows: (1) Objective, (2) Methods, (3) Results, and (4) Conclusion. Under these headings, briefly describe the subject of the article, methods used for the study, basic findings, and author's conclusion. No subtitles may be used in the abstract of a case report. A minimal number of abbreviations and/or acronyms should be used. Abstracts should not contain any references. A maximum of 5 keywords should be included at the end of the abstract. The Medical Subject Headings (MeSH) prepared by the US National Library of Medicine (NLM) may be used as a reference for keywords.

Introduction: State the specific purpose and available data relevant to the study.

Methods: All methods used to select participants and conduct the study should be described in detail. Known methods should be cited. Novel or modified methods used should be described in detail. Doses, concentrations, routes, and duration of administration of drugs and chemical agents should be indicated. A concise report of all statistical methods used for summarizing available data and for testing the proposed hypothesis should be provided under a subtitle, including the p value criteria determined for statistically significant difference. Statistical evaluation conducted should be explained in detail. Standard statistical methods should be used as much as possible. If rarely employed or novel statistical methods were used, then the relevant references should be cited. When necessary, more detailed explanations about unusual, complex or new statistical methods can be provided in separate files for readers as online supplementary data. The commercial name and version number of any statistical software package program used should be provided. For statistical evaluation, the recommendations in the statistics section of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing

and Editing for Biomedical Publication" (<http://www.ICMJE.org>) should be taken into consideration.

Authors who used AI technology to conduct the study should describe its use in this section in sufficient detail to enable replication to the approach, including the tool used, version, and prompts where applicable.

Results: The study results should be presented in logical sequence and in detail. The findings should be supported by figures and tables. Information given in figures and tables should not be repeated in the text unless absolutely required.

Discussion: Data relevant to the study subject matter should be examined, evaluated, and substantiated with references from domestic and international sources. General information irrelevant or superfluous to the report should not be included.

Acknowledgement: The names of individuals who contributed to the study but who fail to meet the criteria of authorship should be mentioned in this section. The written consent of all individuals mentioned should be obtained.

Conflict of Interest: All potential conflicts of interest should be declared under this heading. All affiliations with pharmaceutical firms, biomedical device manufacturers, and other service or product procurers relevant to the subject matter of the study should be explicitly indicated. If no conflict of interest exists, this should be stated as "none declared." Declarations related to conflicts of interest should be placed at the bottom of a separate page after the acknowledgements and before the references. A Conflict of Interest Form will be sent to the authors of accepted papers.

Funding sources: The full name of any sponsoring foundation or institution should be provided.

References: All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text. While citing publications, preference should

be given to the latest, most up-to-date publications. If an ahead-of-print publication is cited, the DOI number should be provided along with the journal abbreviation and the expression "[Epub ahead of print.]" Authors are responsible for the accuracy of references. Journal titles should be abbreviated in accordance with the journal abbreviations in the Index Medicus/ MEDLINE/PubMed. When there are 6 or fewer authors, all authors should be listed. If there are 7 or more authors, the first 6 authors should be listed followed by "et al." In the main text of the manuscript. Reference numbers should be written in square brackets, in compliance with Vancouver style (see. <https://www.ncbi.nlm.nih.gov/books/NBK7256/>). The reference styles for different types of publications are presented in the following examples:

1. Journal: Balci NC, Sirvanci M, Tufek I, Onat L, Duran C. Spontaneous retroperitoneal hemorrhage secondary to subcapsular renal hematoma: MRI findings. *Magn Reson Imaging* 2001;19:1145-8.
2. Articles in press: Roten L, Derval N, Sacher F, Pascale P, Wilton SB, Scherr D, et al. Ajmaline attenuates electrocardiogram characteristics of inferolateral early repolarization. *Heart Rhythm* 2011 Sep 19 [Epub ahead of print], doi:10.1016/j.hrthm.2011.09.013.
3. Book: Brown AM. Physiology of the liver. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
4. Chapter in book: Anderson JL, Muhlestein JB. The role of infection. In: Theroux P, editor. *Acute coronary syndromes: a companion to Braunwald's Heart Disease*. Philadelphia: W.B. Saunders; 2003. p. 88-107.
5. Web page: Nainggolan L. New salt paper causes controversy. *Heartwire*. May 3, 2011. Available at: <http://www.theheart.org/article/1220043.do>. Accessed: June 12, 2011.

Figure Legends: Explanatory notes for each figure should be submitted on a separate page in order of their appearance in the text immediately after the references section under the heading "figure legends." All abbreviations and symbols used in the figure should be defined in alphabetical order.

INSTRUCTIONS FOR THE AUTHORS

Figures: The manuscript will not be evaluated until all figures cited in the text are submitted. The number of figures provided should be in accordance with the content and data presented in the text, and table data should not be repeated in figures. All figures should be sent in individual electronic file format ready for publication with maximum dimensions of 125 cm x 180 cm. Illustrations in color should be in CMYK format and have a minimum resolution of 300 DPI suitable for publication. Figures depicted in gray scale should have a minimum resolution of 600 DPI, and the minimum resolution required for black and white illustrations is 1200 DPI. All figures should be in TIFF format. Figures must not disclose or imply the identity of a specific individual without the written consent of the individual in question.

Tables: Each table should be typed or printed with double-spacing on a separate sheet of paper. Tables should be numbered consecutively in the order of their first citation in the text. The number and title of the table should be placed just above the table. Do not use vertical lines between columns. Horizontal lines should be used only above and below the headings of the columns, and at the bottom of the table. If required, explanatory notes regarding table data should be written in footnotes. All abbreviations and acronyms used in the table should also be explained in alphabetical order in footnotes.

ETHICAL POLICY

NCI follows the ethics flowcharts developed by the Committee on Publication Ethics (COPE) for dealing with cases of possible scientific misconduct and breaches of publication ethics. For detailed information please visit www.publicationethics.org.

All submitted manuscripts are screened with plagiarism software (iThenticate) to detect instances of overlapping and similar text during the evaluation process.

All manuscripts presenting data obtained from research involving human subjects must include a statement that the written informed consent of the participants was obtained and that

the study was approved by an institutional review board or an equivalent body. This institutional approval should be submitted with the manuscript. Authors of case reports must submit the written informed consent of the subject(s) of the report or of the patient's legal representative. Manuscripts with human and animal studies should describe the steps taken to eliminate pain and suffering.

AUTHORSHIP

All individuals listed as "author" in the submitted manuscript must make an adequate contribution to the study, meet the criteria of authorship, and take responsibility for their part of the manuscript. For the sake of the outcomes and the integrity of the study, at least one author should be responsible for each section of the manuscript. All authors mentioned in the cover letter must meet all of the following criteria: (1) substantial contribution to conception, design of the study, analysis, and interpretation of data, or all of these criteria; (2) significant contribution to the drafting of the article or revision of its scientific content; (3) approval of the final version of the article to be published.

In multicentered studies, all individuals who are named as authors under the title of the article should meet all the above-mentioned requirements of authorship. Seeking or providing financial support for the study, and/or data collection do not satisfy the criteria of authorship per se, nor does general support or guidance provided to the study investigators. Individuals who contributed to the study in various ways but who fail to meet the criteria of authorship may be included in the acknowledgements with their written consent. Please refer to the ICMJE website for more information about authorship. Increasing the number of authors unnecessarily is not ethical conduct and to prevent any attempt to seek undue academic prestige or other unethical advantages, the editor may request a declaration from the authors of their individual contributions to the article and publish this information, if deemed appropriate. The sequence of authors' names should be based on a consensus reached by all the participating authors. Due to different specifi-

cations for the sequencing of authors, the order provided will be used unless otherwise stated. Authors may explain the rationale for a different sequence in a footnote.

DECLARATION OF ARTIFICIAL INTELLIGENCE (AI)-ASSISTED TECHNOLOGY IN SCIENTIFIC WRITING

At submission, authors should disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Authors who use such technology should describe, in both the Title Page and the submitted work, how they used it. Authors who used AI technology to conduct the study should describe its use in the methods section in sufficient detail to enable replication to the approach, including the tool used, version, and prompts where applicable. Chatbots (such as ChatGPT) and AI assisted technologies should not be listed as an author or co-author nor cited because they cannot be responsible for the accuracy, integrity, and originality of the work, and these responsibilities are required for authorship. Therefore, humans are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit the result because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors should be able to assert that there is no plagiarism in their paper, including in text and images produced by the AI. Humans must ensure there is appropriate attribution of all quoted material, including full citations.

SUBMISSION OF THE MANUSCRIPT

All manuscripts should be submitted to the NCI via the online submission system. All authors' ORCID numbers need to be submitted when creating an account for correspondence. To obtain an ORCID number, please visit: <https://orcid.org/> For questions or requests related to the submission and evaluation process of manuscripts, the editorial office may be contacted by e-mail at bilgi@kuzeyklinikleri.com.

In compliance with the journal's publication rules, the current status of the manuscript will not be discussed on the phone prior to acceptance for publication. First-time users of the online submission system will need to register. A user name and a code specific to the user will be sent by e-mail. For further details please consult the online manuscript submission page.

REVIEW OF MANUSCRIPTS

In order for an article to be published in the journal it should not be published elsewhere, and must be deemed suitable for publication by the editorial board selected by the NCI Executive Committee. All responsibility for the manuscript belongs to the author(s). The evaluation process of the submitted manuscript will not begin until a document with the signed approval of all authors has been received. During typesetting and other preparation of the manuscript for publication, a Copyright Transfer Form will be sent to the primary author(s) ("guarantors") who will assume responsibility for the manuscript. All submitted manuscripts are first evaluated by the editorial board. At this stage, manuscripts not deemed suitable for publication in NCI, including those not complying with the requirements or without adequate scientific content, will be returned to the authors. Manuscripts found suitable for publication will be sent to reviewers for more detailed evaluation. Acceptability of manuscripts is dependent on originality, scientific content, and the subject of the study, in accordance with the publica-

tion protocol of the journal. All research articles deemed suitable for publication are subjected to a detailed statistical evaluation. The authors are informed of the editors' decision on the acceptability of the manuscript via e-mail, usually within 6 weeks of its submission. The editors do not discuss their decision on the phone. All objections and requests should be communicated to the editors in a written format. If deemed necessary, the editorial board has the right to make modifications to the text without altering the main concept of the manuscript. An offprint of the manuscript will not be sent to the author(s).

Northern Clinics of Istanbul wants reviewers to treat the manuscripts in confidence. Reviewers who seek assistance from a trainee or colleague in the performance of a review should acknowledge these individuals' contributions in the written comments submitted to the editor. Reviewers must maintain the confidentiality of the manuscript, which may prohibit the uploading of the manuscript to software or other AI technologies where confidentiality cannot be assured. Reviewers must request permission from the journal prior to using AI technology to facilitate their review. The material of the manuscripts must not be used or shared in any way until they have been published. Northern Clinics of Istanbul follows the COPE flowchart in cases of suspected reviewer misconduct. Please refer to COPE ethical guidelines for peer reviewers for "Basic principles to which peer reviewers should adhere" and "Expectations from reviewers".

OPEN ACCESS

NCI is a fully open access journal. All articles published in NCI are available on the internet to all users immediately upon publication. Non-commercial use and distribution in any medium is permitted, provided the author and the journal are properly credited.

PUBLICATION CHARGES POLICY

Starting from 15 April 2024, the Northern Clinics of Istanbul will be introducing an Article Processing Charge (APC) of 400 USD (VAT included) for articles published in the journal. This charge is necessary to cover the costs associated with the publication services provided by the journal. These services include article management costs, the production of articles in PDF and other formats, and the distribution of published articles to various venues and other publishing functions.

This measure is essential to sustain the high-quality standards and operational expenses of the journal. While it represents an additional cost for authors, it is a common practice in scientific publishing, particularly in the context of maintaining the viability of publications like open-access journals.

ADDRESS OF CORRESPONDENCE

KARE PUBLISHING

Goztepe Mahallesi, Fahrettin Kerim Gokay Caddesi, No: 200, Daire: 2, Kadikoy, Istanbul, Turkiye
Tel: 0216 550 61 11
Fax: 0216 550 61 12
E-mail: kare@karepb.com